Free Trial

Coeptis Therapeutics (COEP) Competitors

Coeptis Therapeutics logo
$11.63 -0.28 (-2.35%)
Closing price 04:00 PM Eastern
Extended Trading
$12.06 +0.43 (+3.74%)
As of 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

COEP vs. LYEL, IMRX, LIMN, GLSI, NKTX, THTX, IKT, FATE, TNYA, and CGEN

Should you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include Lyell Immunopharma (LYEL), Immuneering (IMRX), Liminatus Pharma (LIMN), Greenwich LifeSciences (GLSI), Nkarta (NKTX), Theratechnologies (THTX), Inhibikase Therapeutics (IKT), Fate Therapeutics (FATE), Tenaya Therapeutics (TNYA), and Compugen (CGEN). These companies are all part of the "pharmaceutical products" industry.

Coeptis Therapeutics vs. Its Competitors

Coeptis Therapeutics (NASDAQ:COEP) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Coeptis Therapeutics has a beta of -0.63, indicating that its share price is 163% less volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500.

Coeptis Therapeutics has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -514,649.22%. Lyell Immunopharma's return on equity of -73.66% beat Coeptis Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Coeptis TherapeuticsN/A -282.39% -127.23%
Lyell Immunopharma -514,649.22%-73.66%-60.99%

In the previous week, Lyell Immunopharma had 1 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 4 mentions for Lyell Immunopharma and 3 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 1.28 beat Lyell Immunopharma's score of 0.94 indicating that Coeptis Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Coeptis Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lyell Immunopharma
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Coeptis Therapeutics has higher earnings, but lower revenue than Lyell Immunopharma. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coeptis TherapeuticsN/AN/A-$10.88M-$5.80-2.01
Lyell Immunopharma$60K3,065.67-$342.99M-$25.00-0.50

13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by company insiders. Comparatively, 22.3% of Lyell Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Lyell Immunopharma has a consensus target price of $15.00, indicating a potential upside of 20.77%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, analysts clearly believe Lyell Immunopharma is more favorable than Coeptis Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coeptis Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Lyell Immunopharma
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Summary

Lyell Immunopharma beats Coeptis Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Coeptis Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COEP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

COEP vs. The Competition

MetricCoeptis TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$41.85M$3.03B$5.74B$9.51B
Dividend YieldN/A2.40%4.60%3.99%
P/E RatioN/A21.1828.1120.03
Price / SalesN/A339.44461.57200.15
Price / CashN/A43.2336.5559.01
Price / Book7.228.368.655.90
Net Income-$10.88M-$55.19M$3.25B$258.66M
7 Day Performance8.90%5.89%4.20%2.23%
1 Month Performance41.83%17.63%10.82%12.76%
1 Year Performance117.30%5.09%34.70%19.36%

Coeptis Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
COEP
Coeptis Therapeutics
0.6865 of 5 stars
$11.63
-2.4%
N/A+117.3%$41.85MN/A0.002Positive News
Gap Up
LYEL
Lyell Immunopharma
2.5117 of 5 stars
$10.28
+8.3%
$15.00
+45.9%
-67.7%$152.25M$60K-0.41270News Coverage
Gap Up
IMRX
Immuneering
3.1424 of 5 stars
$4.22
-0.5%
$13.25
+214.0%
+247.8%$151.88M$320K-2.1560
LIMN
Liminatus Pharma
N/A$5.78
+3.6%
N/AN/A$150.34MN/A0.00N/ANews Coverage
Gap Down
High Trading Volume
GLSI
Greenwich LifeSciences
2.2011 of 5 stars
$11.14
-5.3%
$39.00
+250.1%
-26.1%$148.94MN/A-8.843High Trading Volume
NKTX
Nkarta
1.7718 of 5 stars
$2.08
+8.3%
$14.33
+589.1%
-67.8%$147.60MN/A-1.38140
THTX
Theratechnologies
N/A$3.16
+0.6%
N/A+117.2%$145.30M$84.38M-16.63140
IKT
Inhibikase Therapeutics
1.484 of 5 stars
$1.93
+2.7%
$6.50
+236.8%
+12.8%$143.48MN/A-0.726News Coverage
FATE
Fate Therapeutics
3.6783 of 5 stars
$1.24
+7.8%
$3.83
+209.1%
-75.9%$142.10M$13.63M-0.83550
TNYA
Tenaya Therapeutics
3.8258 of 5 stars
$0.85
-0.7%
$6.25
+634.7%
-77.2%$138.38MN/A-0.73110Positive News
CGEN
Compugen
1.4344 of 5 stars
$1.55
+2.6%
$4.00
+158.1%
-12.0%$138.32M$27.86M-9.6970

Related Companies and Tools


This page (NASDAQ:COEP) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners